Department of Cardiovascular Surgery, The Sakakibara Heart Institute of Okayama, Japan.
Department of Cardiovascular Surgery, The Sakakibara Heart Institute of Okayama, Japan.
J Thorac Cardiovasc Surg. 2017 Jul;154(1):100-106.e1. doi: 10.1016/j.jtcvs.2016.12.060. Epub 2017 Feb 10.
The aim of this study is to evaluate the objective outcomes of conventional total aortic arch repair (CTAR) and hybrid arch repair by using propensity-score matching to reduce selection bias.
Between January 2006 and April 2016, 470 consecutive patients underwent isolated aortic arch repair (excluding hemiarch or partial arch reconstruction, and cases with concomitant cardiac surgeries) at a single cardiovascular institute. We categorized 337 total aortic arch repair with antegrade cerebral perfusion under circulatory arrest as the CTAR group and 58 hybrid aortic arch repair (HAR) with thoracic endovascular aortic repair as the HAR group. Seventy-five patients with scheduled and staged thoracic endovascular aortic repair after total aortic arch repair with elephant trunk were excluded. Then, we compared early and midterm outcomes between the propensity-matched group (43 CTAR vs HAR pairs).
There were no significant differences in 30-day and operative deaths between the CTAR and HAR groups (4.7% [2/43] vs 7.0% [3/43]; P = .4142 and 11.6% [5/43] vs 16.3% [7/43]; P = .5637). Although there were no significant differences in the incidences of other major complications, permanent stroke was observed more frequently in the HAR group (0% [0/43] vs 11.6% [5/43]; P = .0064) compared with the CTAR group. Matching analysis, however, revealed an equivalent 5-year survival rate between the CTAR and HAR groups (80.5% vs 59.9%; P = .1300).
Matching analysis revealed a significantly greater incidence of stroke in the HAR group but equivalent midterm outcomes in the hybrid group compared with the CTAR group.
本研究旨在通过倾向评分匹配来减少选择偏倚,评估传统全主动脉弓修复(CTAR)和杂交弓修复的客观结果。
2006 年 1 月至 2016 年 4 月期间,在一家心血管研究所连续收治 470 例接受单纯主动脉弓修复(不包括半弓或部分弓重建,以及伴有心脏手术的病例)的患者。我们将 337 例在体外循环下进行顺行性脑灌注的全主动脉弓修复患者归入 CTAR 组,58 例采用胸主动脉腔内修复术的杂交主动脉弓修复(HAR)归入 HAR 组。排除 75 例计划分期行全主动脉弓修复后胸主动脉腔内修复术的患者。然后,我们比较了倾向评分匹配组(43 对 CTAR 与 HAR)的早期和中期结果。
CTAR 组和 HAR 组的 30 天和手术死亡率无显著差异(4.7%[2/43]与 7.0%[3/43];P=0.4142 和 11.6%[5/43]与 16.3%[7/43];P=0.5637)。虽然其他主要并发症的发生率无显著差异,但 HAR 组永久性卒中的发生率高于 CTAR 组(0%[0/43]与 11.6%[5/43];P=0.0064)。然而,匹配分析显示 CTAR 组和 HAR 组的 5 年生存率相当(80.5%与 59.9%;P=0.1300)。
匹配分析显示,HAR 组卒中发生率显著增高,但与 CTAR 组相比,杂交组的中期结果相当。